Cargando…
Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines
SIMPLE SUMMARY: Glioblastoma multiforme is the most common primary brain tumor. Unfortunately, it is also one of the cancer types that has the worst morbidity and mortality ratios, so new targets and treatments need to be found. The metabolism of glutamine is fundamental for the proliferation of man...
Autores principales: | De los Santos-Jiménez, Juan, Rosales, Tracy, Ko, Bookyung, Campos-Sandoval, José A., Alonso, Francisco J., Márquez, Javier, DeBerardinis, Ralph J., Matés, José M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856342/ https://www.ncbi.nlm.nih.gov/pubmed/36672480 http://dx.doi.org/10.3390/cancers15020531 |
Ejemplares similares
-
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017) -
Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
por: Giesen, Beatriz, et al.
Publicado: (2021) -
Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells
por: de los Santos-Jiménez, Juan, et al.
Publicado: (2021) -
Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023) -
DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)